Several brokerages have updated their recommendations and price targets on shares of Sarepta Therapeutics (NASDAQ: SRPT) in the last few weeks:
- 9/28/2026 – Sarepta Therapeutics had its “underperform” rating reaffirmed by Needham & Company LLC.
- 9/24/2026 – Sarepta Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 9/23/2026 – Sarepta Therapeutics was upgraded by William Blair to “hold”.
- 9/9/2026 – Sarepta Therapeutics had its “sell” rating reaffirmed by Benchmark Co..
- 9/8/2026 – Sarepta Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 8/19/2026 – Sarepta Therapeutics was downgraded by Weiss Ratings from “sell (d)” to “sell (e+)”.
- 8/12/2026 – Sarepta Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
- 8/8/2026 – Sarepta Therapeutics was downgraded by Wall Street Zen from “buy” to “hold”.
- 8/5/2026 – Sarepta Therapeutics was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
Sarepta Therapeutics, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. Its research platforms include RNA-based technologies, gene therapy and gene-editing approaches designed to address the underlying causes of genetic disorders.
The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for eligible patients with specific genetic mutations, as well as Elevidys, a gene therapy developed to treat certain patients with DMD.
Featured Stories
- Five stocks we like better than Sarepta Therapeutics
- AI Uncertainty Is Rising, But These 3 Chip ETFs Still Have Momentum
- Arhaus Has New Momentum—Could Other Furniture Stocks Be Next?
- Can Boxabl Turn Modular Homes Into AI Data Center Infrastructure?
- Up All Night: How Nasdaq’s 23-Hour Trading Could Wake Up Wall Street
Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
